So we have heard a little bit about an esophageal screening test using a swab, as well as a potential pancreatic screening test. But I noticed that in a recent conference call, the CEO mentioned one "other" test, but chose to not mention the name, as opposed to having mentioned esophageal and pancreatic. This seemed to be by design.
Rumor has it that it is a lung cancer screening test that is blood based.
Anyone hear the same?
This has the makings of something really fun!
Looks like there are a number of Funds that took part in the secondary offering in January at $5.50
Some new fundholders as well, like PrimeCap (7.5 million), Lesa Sroufe (651,000), UBS O'Connor (600,000), Kennedy Capital (240,000), Aeris Capital out of Germany (235,000) and Trexquant Investments (211,300.
Interesting to note, Biotech Fund King-Pin "Wasatch Advisors" out of Utah is a new shareholder as well, albeit relatively small at 150,000. These guys can swing millions of shares if they want to. They are like OrbiMed.
Are they not holding an Investor/Analyst Day in early June?
It would be pretty embarrassing to hold an Investor/Analyst Day and not having anything to announce.
I think that revenues could easily double over the next 12-18 months.
Meanwhile, the stock trades at HALF the price/sales multiple as competitor MiMedx and Osiris.
This stock is an easy double here. The CEO is a proven Winner!
He grew sales to $1.0 Billion at ConvaTech.
All of a sudden, there are no sellers.
Quite a contrast from the first 2.5 days of the week after the USPSTF came out with their recommendation for Mammography.
You can find it on their online website.
3 worldly experts in blood supply safety strongly urging the FDA and world to embrace pathogen inactivation.
This is HUGE for CERS!
What is a Taget price?
You left out the "R"..... is that because you are #$%$???
A $1.6 Billion market cap would be a steal.
Wake me up if we get there.
There are 30 stocks in the index (FBT) and each one of them gets a 3.33% weight.
EXAS is currently at only 2.56% which means that (based on $3.7 billion in the index) there needs to be $28 million worth of buying in order to get EXAS back up to an "equal" weighting. ICPT is at the opposite end of the spectrum, totally overweighted because of its monster rally at over 5.5%